The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Peripheral Arterial Disease

Interventions

DRUG

Rivaroxaban 2.5 Mg Oral Tablet

rivaroxaban 2.5 milligrams twice daily

DRUG

Placebo

placebo

DRUG

Aspirin 81Mg Ec Tab

aspirin 81 milligrams

Trial Locations (1)

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University Medical Center

OTHER